Specialist Updates 
Cardiology

Diabetes drug no better than placebo for MACE, trial shows

But results of the VERTIS CV trial confirm that ertugliflozin cuts admissions for heart failure
Medicom Staff writer
0
4 September 2020
Save
Please login to bookmark Close
doctors recording information on clipboard and tablet

AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.

A trial of ertugliflozin in patients with type 2 diabetes (T2DM) and established atherosclerotic CVD has found no difference in outcomes for major adverse cardiac events (MACE) between the drug and placebo, researchers report.

But the VERTIS CV trial does confirm earlier findings of a reduced risk of admission for heart failure in patients with T2DM taking the SGLT2 inhibitor, with results showing a 30% lower risk of this event in those on the drug.

The findings were announced at the European Society of Cardiology’s 2020 (ESC 2020) virtual congress this week.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .